SKL2 Antibody
Description
Definition and Biological Context
SK2 antibodies target sphingosine kinase 2 (SK2), an enzyme encoded by the SPHK2 gene that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). This lipid mediator regulates cellular processes including apoptosis, proliferation, and immune responses . SK2 is implicated in cancer, neurodegenerative diseases, and metabolic disorders, making its antibodies critical for research and diagnostics .
Application-Specific Performance
-
Immunoblotting: Proteintech’s antibody reliably detects endogenous SK2 in HEK293 and HeLa cells but requires knockout controls in murine systems .
-
Functional Studies: ECM’s antibody is preferred for co-localization studies due to its nuclear and cytoplasmic staining accuracy in human cells .
Validation Protocols
-
Knockout Controls: Essential for confirming specificity, as demonstrated in Sphk2−/− MEFs .
-
Species Cross-Reactivity: Human cell lines (e.g., HEK293) show fewer artifacts compared to mouse models .
Implications for Disease Research
SK2 antibodies have been instrumental in:
-
Cancer Biology: SK2 overexpression correlates with tumorigenesis in breast and colorectal cancers .
-
Neurological Disorders: Aberrant SK2 activity is linked to Alzheimer’s disease via S1P-mediated pathways .
-
Therapeutic Development: Monoclonal SK2 antibodies are being explored for targeted therapies .
Challenges in Antibody Reproducibility
Recent initiatives like YCharOS emphasize the "antibody characterization crisis," revealing that:
Future Directions
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
FAQs for Researchers on SK2 Antibody Applications in Academic Research
Advanced Research Questions
How to resolve discrepancies in SK2 antibody performance across cell lines?
Non-specific binding in MEFs (but not human cells) highlights cell-type-dependent variability . Approach:
-
Perform parallel experiments with multiple cell lines.
-
Combine immunoprecipitation (IP) with mass spectrometry to identify off-target proteins.
-
Use phospho-specific antibodies if studying post-translational modifications (e.g., CK2-mediated phosphorylation alters SK2 stability) .
Case Study: In , CK2 phosphorylation of SALL2 (a zinc-finger protein) was confirmed via λ-phosphatase treatment and in vitro kinase assays, a method applicable to SK2 studies.
Integrated Workflow:
| Step | Method | Purpose |
|---|---|---|
| 1. Knockout | CRISPR/Cas9 in HEK293 | Confirm SK2-dependent phenotypes |
| 2. Localization | Immunofluorescence (ECM Biosciences antibody) | Subcellular SK2 distribution |
| 3. Functional Assay | Sphingosine kinase activity assay | Link localization to enzymatic activity |
Key Finding: SK2’s nuclear localization in HeLa cells suggests non-canonical roles beyond sphingolipid metabolism .
Strategies:
-
Epitope Mapping: Use antibodies targeting non-conserved regions (e.g., ECM Biosciences’ N-terminal epitope) .
-
Cross-Adsorption: Pre-adsorb antibodies with SK1 or other related protein lysates .
-
Computational Modeling: Predict binding modes using biophysical energy landscapes (as in ) to refine antibody selection.
Example: In , phage display libraries were screened against ligand combinations to design antibodies with customized specificity profiles.
Approach:
-
Phosphorylation Analysis: Treat lysates with λ-phosphatase to erase baseline phosphorylation, then use in vitro kinase assays (e.g., CK2) .
-
Ubiquitination Assays: Co-IP SK2 with ubiquitin ligases (e.g., Skp2) .
-
Stability Profiling: Treat cells with proteasome inhibitors (MG132) to assess degradation kinetics .
Data from : CK2 phosphorylates SALL2 at S763/T778/S802/S806, promoting proteasomal degradation—a protocol adaptable to SK2 studies.
Troubleshooting Data Contradictions
Root Causes:
-
Proteolytic Degradation: Use fresh protease inhibitors and avoid freeze-thaw cycles.
-
Alternative Splicing: SK2 has isoforms (e.g., SK2a vs. SK2b) with varying antibody recognition .
-
Post-Translational Modifications: Phosphorylation or ubiquitination may alter electrophoretic mobility .
Resolution: Combine IP with peptide competition assays to confirm target identity .
Factors:
-
Matrix Effects: Saliva has lower IgG titers than blood; dilute samples to reduce mucin interference .
-
Epitope Stability: DBS stabilizes linear epitopes, while saliva may require conformational epitope-targeting antibodies .
Validation Protocol:
Workflow from :
-
Phage Display Selection: Generate libraries against target ligands (e.g., SK2 peptides).
-
High-Throughput Sequencing: Identify enriched CDR3 sequences.
-
Energy Landscape Modeling: Predict binding modes using , optimizing for specificity.
-
In Vitro Testing: Validate top candidates via SPR or BLI.
Outcome: Antibodies with tailored specificity for SK2 over SK1 or other kinases.
